Use of Rabenid for different indications.

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Metabolic Disorders

Background:

• Hyperuricemia is closely linked to obesity, diabetes, atherosclerosis, hypertension, and hyperlipidemia.
• These metabolic and cardiovascular conditions represent significant health risks for many patients.
• Effective management of hyperuricemia may offer broader health benefits.

Purpose of the Study:

• To evaluate the efficacy of Rabenid (sulfinpyrazone) in managing serum uric acid levels.
• To assess the drug's impact on serum cholesterol and triglyceride levels.
• To investigate the prophylactic potential of Rabenid against thrombosis and its overall tolerability.

Main Methods:

• A study involving 95 patients with various diseases treated with Rabenid.
• Objective measurement of serum uric acid levels as a primary parameter.
• Monitoring for new or recurrent thrombosis in at-risk patients during the observation period.

Main Results:

• Rabenid administration resulted in a significant reduction in serum uric acid levels.
• The drug favorably influenced serum cholesterol and triglyceride values.
• No new or recurrent thrombotic events occurred in at-risk patients; Rabenid was generally well-tolerated.

Conclusions:

• Rabenid (sulfinpyrazone) effectively lowers serum uric acid, addressing a key factor in metabolic and cardiovascular diseases.
• The drug shows promise in improving lipid profiles and preventing thrombosis.
• Rabenid is a well-tolerated therapeutic option with significant prophylactic value in patients with associated risk factors.